Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02008773 · ClinicalTrials.gov registry record · Phase 2

A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia

A Phase 2 study, sponsored by Indiana University.

Completed
Registry status
Phase 2
Development phase
170
Enrollment target

NCT02008773 is a Phase 2 study that has completed, run by Indiana University. The registered enrollment target is 170 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02008773, a Phase 2 study, has completed, sponsored by Indiana University.

COMPLETED
Registry status
Phase 2
Development phase
170 participants
Enrollment target

Study Summary

The primary aim of the study is to determine the efficacy of adjunctive valacyclovir, in comparison to placebo, to improve visual (Brief Visuospatial Memory Test) and working (composite score of the Spatial Span and Letter Number Span tests) memory in individuals who are HSV-1 positive and early in the course of schizophrenia. We hypothesize that individuals who are HSV-1 positive, but not those who are HSV-1 negative, will demonstrate significant valacyclovir efficacy for visual and working memory.

Interventions

  • DRUG placebo
  • DRUG Valacyclovir HCI 500 mg tablets

Trial Details

FieldValue
Enrollment Target 170 participants
Start Date 2014-03-26
Est. Completion 2017-06-20
Phase Phase 2

Sponsor

Indiana University

890 total trials

What the Registry Record Tells You About NCT02008773

The ClinicalTrials.gov registry entry for NCT02008773 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.

NCT02008773 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02008773 about?

NCT02008773 is a clinical study titled "A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia". The primary aim of the study is to determine the efficacy of adjunctive valacyclovir, in comparison to placebo, to improve visual (Brief Visuospatial Memory Test) and working (composite score of the Spatial Span and Letter Number Span tests) memory in individuals who are HSV-1 positive and early in ...

What is the current status of trial NCT02008773?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2014-03-26. Estimated completion is 2017-06-20.

What interventions are being tested in trial NCT02008773?

The interventions under investigation include: placebo (DRUG), Valacyclovir HCI 500 mg tablets (DRUG).

Who is sponsoring clinical trial NCT02008773?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.